-
EP4583983
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4583983
| EP4583983 - PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCER [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 13.06.2025 Database last updated on 28.03.2026 | |
| Former | The international publication has been made Status updated on 15.03.2024 | Most recent event Tooltip | 14.11.2025 | Change: Validation states | published on 17.12.2025 [2025/51] | 14.11.2025 | Change - extension states | published on 17.12.2025 [2025/51] | Applicant(s) | For all designated states Cardiff Oncology, Inc. 11055 Flintkote Avenue San Diego CA 92121 / US | [2025/29] | Inventor(s) | 01 /
RIDINGER, Maya San Diego, California 92121 / US | 02 /
ERLANDER, Mark San Diego, CA 92121 / US | [2025/29] | Representative(s) | J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB | [2025/29] | Application number, filing date | 23864080.9 | 11.09.2023 | [2025/29] | WO2023US73865 | Priority number, date | US202263405466P | 11.09.2022 Original published format: US 202263405466 P | US202363515831P | 26.07.2023 Original published format: US 202363515831 P | [2025/29] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2024055039 | Date: | 14.03.2024 | Language: | EN | [2024/11] | Type: | A1 Application with search report | No.: | EP4583983 | Date: | 16.07.2025 | Language: | EN | The application published by WIPO in one of the EPO official languages on 14.03.2024 takes the place of the publication of the European patent application. | [2025/29] | Search report(s) | International search report - published on: | US | 14.03.2024 | Classification | IPC: | A61P35/04, A61K31/519, A61K39/395, A61K31/522 | [2025/29] | CPC: |
A61P35/04 (EP,IL,KR,US);
C07K16/22 (EP,IL,KR,US);
A61K31/519 (EP,IL,KR,US);
A61K31/437 (EP,IL,KR);
A61K31/4745 (EP,IL,KR,US);
A61K31/513 (EP,IL,KR,US);
A61K35/04 (EP,IL,KR,US);
A61K39/395 (EP,IL,KR);
A61K39/3955 (EP,IL,KR,US);
A61K45/06 (EP,IL,KR,US);
A61K9/0053 (IL,KR,US);
A61K2039/505 (EP,IL,KR,US);
A61K2039/545 (EP,IL,KR,US);
A61K2300/00 (EP,IL,KR);
C07K2317/24 (EP,IL,KR);
C07K2317/76 (EP,IL,KR)
(-)
| C-Set: |
A61K31/4745, A61K2300/00 (EP);
A61K31/513, A61K2300/00 (EP);
A61K31/519, A61K2300/00 (EP);
A61K39/395, A61K2300/00 (EP) | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2025/29] | Title | German: | PLK1-INHIBITOR IN KOMBINATION MIT ANTIANGIOGENEN ZUR BEHANDLUNG VON METASTASIERENDEM KREBS | [2025/29] | English: | PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCER | [2025/29] | French: | INHIBITEUR DE PLK1 EN COMBINAISON AVEC DES ANTI-ANGIOGÉNIQUES POUR LE TRAITEMENT DU CANCER MÉTASTATIQUE | [2025/29] | Entry into regional phase | 28.03.2025 | National basic fee paid | 28.03.2025 | Search fee paid | 28.03.2025 | Designation fee(s) paid | 28.03.2025 | Examination fee paid | Examination procedure | 28.03.2025 | Examination requested [2025/29] | 20.10.2025 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 03.07.2025 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A] WO2021226403 (CARDIFF ONCOLOGY INC) [A] 1-7, 12-15, 54-58 * entire document * | [XY] LENZ HEINZ-JOSEF, ANUP KASI, LAWRENCE MENDELSOHN, TIMOTHY LEWIS CANNON, JASON S. STARR, JOLEEN M. HUBBARD, TANIOS S. BEKAII-SAAB, : "A phase 1b/2 trial of the PLK1 inhibitor onvansertib in combination with FOLFIRI-bev in 2L treatment of KRAS-mutated (mKRAS) metastatic colorectal carcinoma (mCRC).", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 40, no. 4-suppl., 19 January 2022 (2022-01-19), US , pages 1 - 3, XP093150418, ISSN: 0732-183X, DOI: 10.1200/JCO.2022.40.4_suppl.100 [X] 1-7, 12-15 * .entire document * [Y] 54-58 DOI: http://dx.doi.org/10.1200/JCO.2022.40.4_suppl.100 | [Y] ROCCHETTI MAURIZIO; GERMANI MASSIMILIANO; BENE FRANCESCA DEL; POGGESI ITALO; MAGNI PAOLO; PESENTI ENRICO; NICOLAO GIUSEPPE DE: "Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts", CANCER CHEMOTHERAPY AND PHARMACOLOGY, SPRINGER VERLAG , BERLIN, DE, vol. 71, no. 5, 21 February 2013 (2013-02-21), DE , pages 1147 - 1157, XP035339855, ISSN: 0344-5704, DOI: 10.1007/s00280-013-2107-z [Y] 54-58 * . entire document * DOI: http://dx.doi.org/10.1007/s00280-013-2107-z | [A] SHARMA MANISH R, DANIEL ISAAC; RYAN RAMAEKERS; MAYA RIDINGER; MARK ERLANDER; LAWRENCE MENDELSOHN: "Abstract 425: Expanded access program of the PLK1 inhibitor onvansertib for treatment of patients with KRAS-mutant metastatic colorectal cancer ", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 81, no. 13_suppl., 1 July 2021 (2021-07-01), US, pages 1 - 4, XP093150420, ISSN: 0008-5472, DOI: 10.1158/1538-7445.AM2021-425 [A] 1-7, 12-15, 54-58 * .entire document * DOI: http://dx.doi.org/10.1158/1538-7445.AM2021-425 | [A] LENZ HEINZ-JOSEF, DANIEL H. AHN, MAYA RIDINGER, MARK G. ERLANDER, AND AFSANEH BARZI: "A phase Ib/II study of onvansertib (PCM-075) in combination with FOLFIRI and bevacizumab for second-line treatment of metastatic colorectal cancer (mCRC) in patients with a KRAS mutation. ", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 38, no. 4-suppl., 4 February 2020 (2020-02-04), US , pages 1 - 2, XP093150427, ISSN: 0732-183X [A] 1-7, 12-15, 54-58 * .entire document * |